A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

Background: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist li...

Full description

Bibliographic Details
Main Authors: Roche, M., Salimi, H., Duncan, R., Wilkinson, B., Chikere, K., Moore, M., Webb, N., Zappi, H., Sterjovski, J., Flynn, J., Ellett, A., Gray, L., Lee, B., Jubb, B., Westby, M., Ramsland, Paul, Lewin, S., Payne, R., Churchill, M., Gorry, P.
Format: Journal Article
Published: 2013
Online Access:http://hdl.handle.net/20.500.11937/20036

Internet

http://hdl.handle.net/20.500.11937/20036

Similar Items